Fibrocell Science (FCSC) Return on Equity ROE from the third quarter 2019 to third quarter 2018 and annually, average high and low, overall ranking from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Fibrocell Science, Inc.  (FCSC)

Fibrocell Science's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Fibrocell Science in the third quarter 2019?
Fibrocell Science, Inc. recorded a cumulative net loss of $-1 million during 12 months ending in the third quarter 2019, resulting in a negative return on equity (ROE) of -11.97%.

Within the Major Pharmaceutical Preparations industry 80 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2019 from 412 to 3017.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Equity Change 5.07 % 91.08 % -4.76 % 6.11 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 3 -12 -11 -6
Return On Equity (TTM) -11.97 % 27.9 % -131.86 % -121.89 % -71.71 %
FCSC's Total Ranking # 3017 # 412 # 0 # 0 # 0
Equity (TTM) in Millions 11 18 6 10 10
Seq. Equity Change -40.22 % 198.33 % -37.22 % -6.16 % 8.71 %
Seq. Net Income Change - - - - -

Back to FCSC Management Effectiveness >> FCSC's 5 Years Annual ROE >> Compare FCSC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 81
Sector # 245
Overall # 3017

Return On Equity Statistics
High Average Low
27.9 %
-204.38 %
-920.22 %
(Jun 30 2019)   (Sep 30 2017)





FCSC Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Equity in Millions 10 9 8 14 30
Y / Y Equity Change 6.11 % 14.58 % -44.65 % -53.29 % -38.77 %
Net Income in Millions -11 -20 -15 -34 -26
Y / Y Net Income Change - - - - -
Return On Equity -112.9 % -225.81 % -194.53 % -242.58 % -84.35 %

Back to FCSC Management Effectiveness >> FCSC's 5 Years Annual ROE >> Compare FCSC ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FCSC's' Return on Equity at Yahoo Finance
FCSC's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FCSC's Competitors
Subscribers only: Roe for Fibrocell Science's Suppliers
Subscribers only: Return On Equity for FCSC's Customers




Companies with similar Return On Equity at Sep 30 2019, within Healthcare Sector ROE

Date modified: 2026-09-08T15:09:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.